Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | June 22, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SYNLOGIC, INC.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22 | Direct | 30,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 335,964 · Balance 897,642 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 897,642 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly 2001 Trust | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-13 · Other · Disposed 15,233 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly Irrevocable GST Trust of 2019 | 0 |
Reported balance
After 2025-05-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-05-13 · Other · Disposed 41,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.97 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-13 · Disposition to issuer · Disposed 469,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 4
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 14,416 · Balance 1,245 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 4 · 2025-06-02 · Disposition to issuer · Disposed 1,245 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly 2001 Trust | 0 |
Reported balance
After 2025-05-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-30 · Other · Disposed 2,284 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly Irrevocable GST Trust of 2019 | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 6,150 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 4, 2020 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $73.84 | $0.00 |
DisclosureSEC source: 0001562180-20-002149 · primarydocument.xml · derivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-03-02 F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002149 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,407 F1 · security: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/04/2021, 25% on 01/04/2022, 25% on 01/04/2023, and 25% on 01/04/2024. F2 · balance_after: 195 shares were acquired under the bluebird bio, Inc. employee stock purchase plan. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 17:33 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 10,163 | $89.97 | $914,377.31 |
DisclosureSEC source: 0001562180-20-000306 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,712 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $89.50 to $90.42. The average weighted price was $89.9712. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:16 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0000899243-19-015998 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:48 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $134.63 | $0.00 |
DisclosureSEC source: 0001209191-19-007452 · doc4.xml · derivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2020 and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:48 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007452 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,203 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,529 | $114.31 | $289,079.87 |
DisclosureSEC source: 0001209191-19-003089 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,203 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range of prices for the transaction reported on this line was $113.78 to $114.72. The average weighted price was $114.306. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4,845 | $113.29 | $548,885.69 |
DisclosureSEC source: 0001209191-19-003089 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,732 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range of prices for the transaction reported on this line was $112.73 to $113.70. The average weighted price was $113.2891. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 20:05 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0000899243-18-016593 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to the reporting person's continued service as a director of the Corporation. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $205.25 | $0.00 |
DisclosureSEC source: 0001209191-18-007410 · doc4.xml · derivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-02-01 F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2019, and in 36 equal monthly installments. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007410 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,577 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022. F2 · balance_after: 280 shares were acquired under the bluebird bio, Inc. employee stock purchase plan on January 31, 2018. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 712 | $174.17 | $124,008.97 |
DisclosureSEC source: 0001209191-18-002904 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,297 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $173.85 to $174.35. The average weighted price was $174.1699. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4,723 | $173.26 | $818,288.56 |
DisclosureSEC source: 0001209191-18-002904 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,009 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $172.85 to $173.80. The average weighted price was $173.2561. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:30 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 17,143 | $0.00 Strike: $9.70 | $0.00 |
DisclosureSEC source: 0000899243-18-000272 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,143 Underlying: Common Stock · 17,143 shares Expires 2027-12-29 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of August 28, 2017 subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 37,873 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · derivative · entry 11 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,355 Underlying: Common Stock · 37,873 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,530 | $188.49 | $476,881.47 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 9 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,732 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F9 · price: The range of prices for the transaction reported on this line was $188.1500 to $188.8000. The average weighted price was $188.4907. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 5,700 | $187.57 | $1,069,134.75 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 8 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,262 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F8 · price: The range of prices for the transaction reported on this line was $187.0500 to $188.0000. The average weighted price was $187.5675. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 12,006 | $186.56 | $2,239,860.97 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 7 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F7 · price: The range of prices for the transaction reported on this line was $186.0500 to $187.0000. The average weighted price was $186.5618. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 16,369 | $185.41 | $3,035,040.13 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 6 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F6 · price: The range of prices for the transaction reported on this line was $185.0500 to $186.0000. The average weighted price was $185.4139. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 18,930 | $184.53 | $3,493,130.18 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 5 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,337 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F5 · price: The range of prices for the transaction reported on this line was $184.0500 to $185.0000. The average weighted price was $184.5288. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 19,221 | $183.46 | $3,526,217.39 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 4 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,267 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F4 · price: The range of prices for the transaction reported on this line was $183.0500 to $184.0000. The average weighted price was $183.4565. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 27,797 | $182.49 | $5,072,655.07 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,488 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F3 · price: The range of prices for the transaction reported on this line was $182.0500 to $183.0000. The average weighted price was $182.4893. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 14,947 | $181.72 | $2,716,198.73 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,285 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $181.0500 to $182.0000. The average weighted price was $181.7220. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 37,873 | $5.50 | $208,316.65 |
DisclosureSEC source: 0001209191-17-065896 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 2,127 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-059148 · doc4.xml · derivative · entry 4 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,228 Underlying: Common Stock · 2,127 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,127 | $145.17 | $308,779.36 |
DisclosureSEC source: 0001209191-17-059148 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,359 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $145.00 to $145.30. The average weighted price was $145.1713. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 2,127 | $5.50 | $11,699.35 |
DisclosureSEC source: 0001209191-17-059148 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,700 | $145.26 | $537,454.97 |
DisclosureSEC source: 0001209191-17-057840 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,359 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F3 · price: The range of prices for the transaction reported on this line was $145.00 to $145.60. The average weighted price was $145.2581. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,350 | $145.02 | $485,812.65 |
DisclosureSEC source: 0001209191-17-057840 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,059 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $145.00 to $145.15. The average weighted price was $145.0187. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:13 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 10,823 | $145.05 | $1,569,840.43 |
DisclosureSEC source: 0001209191-17-057465 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,409 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $145.00 to $145.40. The average weighted price was $145.0467. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 6,364 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-051249 · doc4.xml · derivative · entry 5 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,355 Underlying: Common Stock · 6,364 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vest over a four-year period, at a rate of twenty-five percent (25%) on May 1, 2014, and in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 22,500 | $130.04 | $2,925,983.25 |
DisclosureSEC source: 0001209191-17-051249 · doc4.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,232 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F3 · price: The range of prices for the transaction reported on this line was $130.00 to $130.30. The average weighted price was $130.0437. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 6,364 | $5.50 | $35,004.55 |
DisclosureSEC source: 0001209191-17-051249 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 24,333 | $115.09 | $2,800,460.64 |
DisclosureSEC source: 0001209191-17-051249 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,368 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $115.00 to $115.65. The average weighted price was $115.0890. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 30, 2017 Filed Aug 31, 2017 16:16 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 25,667 | $115.18 | $2,956,307.09 |
DisclosureSEC source: 0001209191-17-050892 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,701 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $115.00 to $115.75. The average weighted price was $115.1793. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 20:13 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 2,857 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0000899243-17-021269 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2027-08-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| June 29, 2017 Filed Aug 31, 2017 16:16 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-050892 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,368 Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 11,288 | $108.52 | $1,225,025.68 |
DisclosureSEC source: 0001209191-17-042269 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,368 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F3 · price: The range of prices for the transaction reported on this line was $108.10 to $109.00. The average weighted price was $108.5246. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 16:01 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 13,712 | $107.65 | $1,476,137.94 |
DisclosureSEC source: 0001209191-17-042269 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2016. F2 · price: The range of prices for the transaction reported on this line was $107.10 to $108.05. The average weighted price was $107.6530. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $75.60 | $0.00 |
DisclosureSEC source: 0001209191-17-007616 · doc4.xml · derivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-02-01 F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2018 and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007616 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,368 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2018, 25% on 01/04/2019, 25% on 01/04/2020, and 25% on 01/04/2021. F2 · balance_after: 522 shares were acquired under the bluebird bio, Inc. employee stock purchase plan on January 31, 2017. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,024 | $67.10 | $135,810.40 |
DisclosureSEC source: 0001209191-17-002922 · doc4.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,346 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $67.00 to $67.50. The average weighted price was $67.10. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2016 Filed Jan 9, 2017 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002922 · doc4.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,370 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.